| Dr Edmund Hsu, MD | |
|
101 The City Dr S, Orange, CA 92868-3201 | |
| (714) 456-7890 | |
| Not Available |
| Full Name | Dr Edmund Hsu |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 10 Years |
| Location | 101 The City Dr S, Orange, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780188136 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A173644 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of California Irvine Medical Center | Orange, CA | Hospital |
| Catalina Island Medical Center | Avalon, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of | 7517869605 | 54 |
News Archive
Democrats worry that talking about the health law will not net them any positive gains in elections this year. House Speaker John Boehner also took to the air Saturday to hammer President Obama on jobs and health care.
SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, won the Gold 2014 International MarCom Award for its SI Joint Patient Community website and an Honorable Mention for the SI Buddy Patient Networking Program.
Interim six month clinical results on the use of the FlexStent Femoropopliteal Self Expanding Stent System in the Superficial Femoral Artery were presented today at the VIVA conference by Dr. William Gray of NY Columbia-Presbyterian Hospital.
ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.
More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.
› Verified 9 days ago
| Entity Name | Faculty Physicians And Surgeons Of Llusm |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205009917 PECOS PAC ID: 1153227814 Enrollment ID: O20031211000981 |
News Archive
Democrats worry that talking about the health law will not net them any positive gains in elections this year. House Speaker John Boehner also took to the air Saturday to hammer President Obama on jobs and health care.
SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, won the Gold 2014 International MarCom Award for its SI Joint Patient Community website and an Honorable Mention for the SI Buddy Patient Networking Program.
Interim six month clinical results on the use of the FlexStent Femoropopliteal Self Expanding Stent System in the Superficial Femoral Artery were presented today at the VIVA conference by Dr. William Gray of NY Columbia-Presbyterian Hospital.
ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.
More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.
› Verified 9 days ago
| Entity Name | Regents Of The University Of |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154379394 PECOS PAC ID: 7517869605 Enrollment ID: O20040120001119 |
News Archive
Democrats worry that talking about the health law will not net them any positive gains in elections this year. House Speaker John Boehner also took to the air Saturday to hammer President Obama on jobs and health care.
SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, won the Gold 2014 International MarCom Award for its SI Joint Patient Community website and an Honorable Mention for the SI Buddy Patient Networking Program.
Interim six month clinical results on the use of the FlexStent Femoropopliteal Self Expanding Stent System in the Superficial Femoral Artery were presented today at the VIVA conference by Dr. William Gray of NY Columbia-Presbyterian Hospital.
ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.
More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.
› Verified 9 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548667843 PECOS PAC ID: 6103739131 Enrollment ID: O20040121000458 |
News Archive
Democrats worry that talking about the health law will not net them any positive gains in elections this year. House Speaker John Boehner also took to the air Saturday to hammer President Obama on jobs and health care.
SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, won the Gold 2014 International MarCom Award for its SI Joint Patient Community website and an Honorable Mention for the SI Buddy Patient Networking Program.
Interim six month clinical results on the use of the FlexStent Femoropopliteal Self Expanding Stent System in the Superficial Femoral Artery were presented today at the VIVA conference by Dr. William Gray of NY Columbia-Presbyterian Hospital.
ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.
More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edmund Hsu, MD 200 S Manchester Ave Ste 300, Orange, CA 92868-3219 Ph: (714) 456-2986 | Dr Edmund Hsu, MD 101 The City Dr S, Orange, CA 92868-3201 Ph: (714) 456-7890 |
News Archive
Democrats worry that talking about the health law will not net them any positive gains in elections this year. House Speaker John Boehner also took to the air Saturday to hammer President Obama on jobs and health care.
SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, won the Gold 2014 International MarCom Award for its SI Joint Patient Community website and an Honorable Mention for the SI Buddy Patient Networking Program.
Interim six month clinical results on the use of the FlexStent Femoropopliteal Self Expanding Stent System in the Superficial Femoral Artery were presented today at the VIVA conference by Dr. William Gray of NY Columbia-Presbyterian Hospital.
ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.
More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.
› Verified 9 days ago
Joseph Villarreal, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 101 The City Dr S, Building 1a, Room 1009, Orange, CA 92868 Phone: 714-456-5239 | |
Scott Rudkin, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: Uci Medical Center, 101 The City Drive South, Orange, CA 92868 Phone: 714-456-2986 | |
Joelle Reynard, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Building 1a, Room 1009, Orange, CA 92868 Phone: 714-456-5239 | |
Dr. Inna Shniter, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1100 W Stewart Dr, Orange, CA 92868 Phone: 714-771-8113 | |
John C Fox, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: Uci Medical Center, 101 The City Drive South, Orange, CA 92868 Phone: 714-456-2986 | |
Miss Shannon Louise Toohey, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 101 The City Drive South, Bldg 200 , Suite 710, Rt 128-01, Orange, CA 92868 Phone: 715-456-5239 | |
Wirachin Hoonpongsimanont, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-5705 |